MARKET

OPK

OPK

Opko Health
NASDAQ
1.540
-0.050
-3.14%
Pre Market: 1.530 -0.01 -0.65% 05:52 09/10 EDT
OPEN
1.580
PREV CLOSE
1.590
HIGH
1.595
LOW
1.530
VOLUME
1.38K
TURNOVER
0
52 WEEK HIGH
1.730
52 WEEK LOW
0.9769
MARKET CAP
1.15B
P/E (TTM)
-15.9585
1D
5D
1M
3M
1Y
5Y
1D
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
Barchart · 1d ago
Weekly Report: what happened at OPK last week (0831-0904)?
Weekly Report · 2d ago
Weekly Report: what happened at OPK last week (0824-0828)?
Weekly Report · 08/31 10:24
What OPKO Health (OPK)'s Royalty‑Backed, Capped‑Repayment Financing Deal Means For Shareholders
Simply Wall St · 08/27 00:37
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
NASDAQ · 08/24 15:15
Weekly Report: what happened at OPK last week (0817-0821)?
Weekly Report · 08/24 10:25
SA Asks: What are the most promising oncology companies right now?
Seeking Alpha · 08/22 21:57
Opko’s CTAP101 Pediatric Trial: A New Angle on Kidney Care Growth
TipRanks · 08/20 16:31
More
About OPK
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

Webull offers OPKO Health Inc stock information, including NASDAQ: OPK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OPK stock methods without spending real money on the virtual paper trading platform.